XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status.
Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology, will be leading the study which is planned to enroll a total of 16 patients at the Cedars-Sinai Medical Center. Onivyde will be given intravenously with MABp1 and 5-fluorouracil/folinic acid every two weeks until disease progression.
Dr. Hendifar commented, "The results to date with treatment of MABp1 show much promise as an effective therapy in this setting. I look forward to evaluating this combination therapy to determine its safety and clinical benefit."
Despite decades of clinical trials, the prognosis for advanced pancreatic cancer is poor . The 5-year survival has remained close to 5% and unchanged despite improvements in chemotherapeutics, surgical outcomes, and diagnostic techniques [1, 2]. Advanced pancreatic adenocarcinoma is characterized by progressive weight loss and nutritional deterioration . It is estimated that up to 80% of these patients present with cachexia . This syndrome has been linked not only to survival, but also to alterations in host defenses, functional ability, and quality of life. In a Phase III clinical study, MABp1 was found to improve clusters of symptoms that included reduced pain, fatigue, improved appetite and increased lean body mass. Patients that had these improvements were found to have reduced disease progression and serious adverse events, and about a three-fold improvement in survival.
Other than multi-agent cytotoxic therapy there have been no treatment advances for pancreatic cancer or its associated cachexia. Despite the availability of effective chemotherapy, only between 15-40% of pancreatic cancer patients are able to receive second line treatment. Importantly, cachexia and its associated fatigue and deconditioning, may explain the difficulty in providing continued therapy after progression in the first-line. It is hoped that MABp1 used in combination with Onivyde will help control disease, reduce symptoms and allow patients to receive treatment longer, thereby improving outcomes.
About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1. Li, D., et al., Pancreatic cancer. Lancet, 2004. 363(9414): p. 1049-57.
2. Panagiotarakou, M., et al., Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care. Jop, 2012. 13(4): p. 342-4.
3. Splinter, T.A., Cachexia and cancer: a clinician's view. Ann Oncol, 1992. 3 Suppl 3: p. 25-7.
4. Ryan, D.P. and M.L. Grossbard, Pancreatic Cancer: Local Success and Distant Failure. Oncologist, 1998. 3(3): p. 178-188.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
QC Games Set to Revitalize the Co-Op Action RPG Genre With Announcement of Breach21.8.2018 06:00 | Pressemelding
Ex-BioWare Members to Unveil Their New AAA Game Project at Gamescom 2018 AUSTIN, Texas, Aug. 21, 2018 (GLOBE NEWSWIRE) -- QC Games, an independent game developer comprised of AAA veterans and cutting-edge creators, today announced its first game project, Breach , a co-op action RPG. Revitalizing the genre by fusing RPG-like depth, an open class system, and explosive third-person action mechanics, with ever-changing mission challenges, Breach empowers players to build up their ideal hero and battle monsters on a Modern Earth that has collided with a parallel Mythological Earth. Breach is the three-year game development project led by President/CEO Dallas Dickinson and Game Director/CCO Gabe Amatangelo, former BioWare team members who worked on major titles such as, Star Wars: The Old Republic, the Dragon Age series, and the highly-praised, unfinished Shadow Realms. Watch the Breach Announcement Trailer HERE : https://www.youtube.com/watch?v=Si_9mpi89BY Download the Breach Announcement T
Sonos Announces Date for Fiscal Third Quarter 2018 Earnings Conference Call20.8.2018 22:14 | Pressemelding
SANTA BARBARA, Calif., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Sonos, Inc. (“Sonos”) (Nasdaq: SONO) today announced that after market close on Monday, September 10, 2018, the company will report financial results for the fiscal third quarter ended June 30, 2018 in a letter to shareholders, which will be made available on the investor relations section of its website. In addition, the company will host a conference call and Q&A to discuss the results on the same day at 5:00 p.m. Eastern Time. A live webcast and replay of the conference call and Q&A will be accessible at: https://investors.sonos.com/news-and-events/default.aspx. The replay will be available for at least one year following completion of the call. The conference call may also be accessed by dialing (866) 393-4306, with conference ID 6098946. Participants outside the U.S. can dial toll-free (734) 385-2616. About Sonos Sonos is the leading multi-room wireless smart home sound system. As the inventor of multi-room wireless home aud
SEMAFO Updates on Security in Burkina Faso20.8.2018 16:29 | Pressemelding
MONTREAL, Aug. 20, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX, OMX: SMF) announces an update on its security measures in Burkina Faso following two armed incidents last week. The Mana and Boungou Mines continue to operate without interruption. Boungou Mine The transport of personnel and supplies has resumed between the Boungou Mine and Ouagadougou under our adjusted security protocol. All expatriate employees are now being transported by helicopter between the two locations. In addition, a ground military force has been deployed on the route between the mine and the capital city. These measures, combined with a heightened escort presence, will ensure transportation of national employees to and from the mine to their villages. Mana Mine Further investigation into Friday’s incident revealed that our employee bus had the misfortune of driving into an ongoing hold-up by bandits on the main Bobo road. This led to an exchange of gunfire, as previously reported. As part of our new security mea
CamundaCon 2018 to Feature Speakers from Goldman Sachs, 24 Hour Fitness, Universal Music and Vodafone20.8.2018 14:00 | Pressemelding
CamundaCon Will Convene 400+ Software Architects, IT Managers and DevOps Professionals to Discuss Workflow Automation Challenges in the Age of Containers and Microservices BERLIN, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Camunda today announced the agenda for CamundaCon, the preeminent conference focused on new innovation in workflow automation for digital businesses. The two-day conference will feature twenty three sessions across two tracks and will take place September 20-21, 2018, at Radialsystem Berlin. Hundreds of participants will gather to discuss the rise of microservices and event-driven architectures in business process management (BPM), and the key role workflow automation is playing in digital transformation. To see full agenda or to register to attend, please visit https://camunda.com/events/camundacon/. The workflow automation market is expected to reach nearly $17 billion by 2023, up from $4.7 billion in 2017.1 As companies across industries accelerate their digital transforma
Ondot’s Mobile Card Controls Provide Protection to Thousands of Banks from ATM Heist Threat17.8.2018 22:47 | Pressemelding
-Card controls counter threat of FBI’s warning on unlimited ATM cash out crime - Santa Clara, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- US mainstream media is reporting on a FBI warning to banks of an impending cybercrime wave targeting ATMs in which thieves seek to steal millions of dollars by using cloned cards for fraudulent withdrawals. Ondot, the global leader in mobile payments services, provides consumers a simple protection with mobile-based card controls that can restrict ATM transactions without completely shutting off the card for legitimate needs. Ondot’s mobile controls can give consumers the ability to restrict transactions specifically for ATMs while leaving their cards active for in-person purchases, eCommerce, and other purchases. By locking the account’s use at an ATM, consumers can work with their financial institution to ensure other security best practices are in place while knowing that even a spoofed card will be unable to withdraw cash. If emergency cash is need
SEMAFO: Armed Incident in Bobo Area17.8.2018 15:48 | Pressemelding
MONTREAL, Aug. 17, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) regrets to report that a bus transporting employees from the town of Bobo-Dioulasso to the Mana Mine in Burkina Faso was shot at by armed bandits this morning. In the exchange of fire between the policemen and bandits, one SEMAFO national employee and one sub-contractor employee lost their lives. Operations at the Mana Mine, located 80 kilometers from the incident, are not affected. Early analysis suggests that this incident and the armed incident that occurred in the Est region six days ago are unrelated. However, the Corporation will be increasing its security measures at Mana and take appropriate steps to ensure the safety of the mine and of its employees. The Corporation would like to express its sincere sympathy to families of the victims. About SEMAFO SEMAFO is a Canadian-based mining company with gold production and exploration activities in West Africa. The Corporation operates the Mana Mine in Burkina
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom